Back

Ascletis reports 48.9% placebo-adjusted PASI reduction for ASC50 in psoriasis trial

Verifying
  • Ascletis reported positive ASC50 results from a 28-day psoriasis proof-of-concept trial.
  • ASC50 delivered a 48.9% placebo-adjusted PASI reduction after once-daily 200 mg treatment.
  • The U.S. Phase I study enrolled mild-to-moderate plaque psoriasis patients under NCT07024602.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.